MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents

Journal of Magnetic Resonance Imaging

Volumn 39, Issue 5, 2014, Pages 1259-1264

  Thomeer, Maarten G ^a   Willemssen, Francois E ^a   Biermann, Katharina K ^a   El Addouli, Haroun ^a   De Man, Rob A ^a   Ijzermans, Jan N ^a   Dwarkasing, Roy S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

gadobenate dimeglumine; gadoxetate disodium; hepatocellular adenoma; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID; CONTRAST MEDIUM; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FATTY LIVER; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER CELL; LIVER INJURY; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; COMPLICATION; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; FEMALE; IMAGE ENHANCEMENT; LIVER TUMOR; MALE; MIDDLE AGED; NODULAR HYPERPLASIA; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADENOMA, LIVER CELL; ADULT; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOCAL NODULAR HYPERPLASIA; HEPATITIS; HEPATOCYTES; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84898422256     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24281     Document Type: Article

References (21)

1. Hussain SM, van den Bos IC, Dwarkasing RS, Kuiper JW, den Hollander J,. Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis. Eur Radiol 2006; 16: 1873-1886.
2. Nagorney DM,. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995; 19: 13-18.
3. van Aalten SM, Terkivatan T, de Man RA, et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences. Dig Surg 2010; 27: 61-67.
4. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011; 53: 1182-1191.
5. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 2004; 24: 3-17; discussion 18-19.
6. van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology 2011; 261: 172-181.
7. Fidler J, Hough D,. Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology 2011; 53: 678-682.
8. Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL,. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 2011; 31: 1547-1568.
9. Nakamura Y, Tashiro H, Nambu J, et al. Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: tumor-by-tumor analysis in explant livers. J Magn Reson Imaging 2013; 37: 684-691.
10. van Kessel CS, de Boer E, Kate FJ, Brosens LA, Veldhuis WB, van Leeuwen MS,. Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI. Abdom Imaging 2012 [Epub ahead of print].
11. Grazioli L, Morana G, Kirchin MA, Schneider G,. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177.
12. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005; 128: 1211-1218.
13. van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN,. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 2011; 55: 120-125.
14. Landis JR, Koch GG,. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
15. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50: 481-489.
16. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H,. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008; 48: 808-818.
17. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007; 46: 140-146.
18. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-748.
19. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004; 126: 1323-1329.
20. Yoneda N, Matsui O, Kitao A, et al. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 2012; 30: 777-782.
21. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging - correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-826.